Robert S. Radie

Mr. Radie has more than three decades of experience working in both public and private pharmaceutical and biotech companies across a range of therapeutic areas. Prior to his current role as Chairman and CEO of Neuraptive Therapeutics, he served as President, CEO and Director of Zyla Life Sciences. His other roles across the life sciences industry include as President and CEO of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur, President and CEO of Transmolecular, Inc., a biotechnology company developing cancer diagnostic and treatment products, and Chief Business Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick Pharmaceuticals, he served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company.

He currently serves as Chairman of the Board of Rockwell Medical, and as a member on the Board of Directors of Valsource, Inc. He also serves as Chairman of the Board at Horse Power For Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Previously, Mr. Radie served as a Director of Paratek Pharmaceuticals, Inc., Affinium Pharmaceuticals, Ltd. and Veloxis Pharmaceuticals AS.

Mr. Radie received his B.S. in Chemistry from Boston College.